Aptorum Group (NASDAQ:APM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aptorum Group (NASDAQ:APM) from a sell rating to a hold rating in a research note released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Aptorum Group Stock Down 4.8%

APM stock opened at $1.58 on Friday. The firm’s fifty day simple moving average is $1.88 and its 200-day simple moving average is $1.34. Aptorum Group has a 12 month low of $0.46 and a 12 month high of $7.49.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.